PolyPid
$ 4.29
0.94%
25 Feb - close price
- Market Cap 77,367,000 USD
- Current Price $ 4.29
- High / Low $ 4.33 / 4.20
- Stock P/E N/A
- Book Value 0.60
- EPS -2.09
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -3.66 %
- 52 Week High 5.12
- 52 Week Low 2.30
About
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Analyst Target Price
$12.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-02-14 | 2023-11-08 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.41 | -0.37 | -0.78 | -0.7 | -1.07 | -1.22 | -1.25 | -1.37 | -3.84 | -3.4 | -10.8 | -8.4 |
| Estimated EPS | -0.33 | -0.52 | -0.55 | -0.82 | -0.88 | -1 | -1.3 | -1.41 | -4.29 | -4.43 | -13.32 | -4.8 |
| Surprise | -0.08 | 0.15 | -0.23 | 0.12 | -0.19 | -0.22 | 0.05 | 0.04 | 0.45 | 1.03 | 2.52 | -3.6 |
| Surprise Percentage | -24.2424% | 28.8462% | -41.8182% | 14.6341% | -21.5909% | -22% | 3.8462% | 2.8369% | 10.4895% | 23.2506% | 18.9189% | -75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.43 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PYPD
2026-02-25 13:53:15
PolyPid (PYPD) announced its senior management will participate in two investor conferences in March 2026. These include the Citizens 2026 Life Sciences Conference in Miami and the 38th Annual ROTH Conference in Dana Point, California. Both events will feature fireside chats, and investors can request one-on-one meetings with PolyPid management.
2026-02-15 09:57:51
PolyPid Ltd. (NASDAQ:PYPD) saw its short interest increase by 44.8% in January, reaching 27,918 shares. The company reported a Q4 EPS miss, posting -$0.41 against a consensus of -$0.34, leading analysts to project continued losses for the current year. Despite mixed Wall Street sentiment with a "Moderate Buy" consensus and a $12.25 price target, concerns about cash burn persist, although management highlighted a potential 2026 catalyst.
2026-02-13 01:27:40
PolyPid (PYPD) reported its Q4 and full-year 2025 financial results, alongside significant corporate updates. The company received positive pre-NDA feedback from the FDA for D-PLEX100, its drug for preventing surgical site infections, and plans to begin a rolling NDA submission by the end of Q1 2026. PolyPid also announced advanced discussions for a U.S. commercial partnership for D-PLEX100, while reporting a full-year net loss of $34.2 million and cash, cash equivalents, and short-term deposits of $12.9 million as of December 31, 2025.
2026-02-12 13:58:00
PolyPid's recent earnings call highlighted significant clinical and regulatory progress, particularly with their D-PLEX100 drug, which met its primary endpoint in Phase III trials. The company anticipates a transformative 2026 with an FDA rolling submission planned for Q1 and advanced U.S. partnership talks underway. Despite this, financial pressures due to a short cash runway and increasing operating costs remain a key concern for investors.
2026-02-12 12:58:09
PolyPid Ltd. shared its Q4 and full-year 2025 financial results, highlighting a pivotal year marked by successful completion of the SHIELD II Phase III trial for D-PLEX100. The company is preparing for a rolling New Drug Application (NDA) submission for D-PLEX100 by the end of Q1 2026 and is in advanced stages of U.S. partnership discussions. They also introduced Kynatrix as their next-generation technology platform, expanding beyond D-PLEX100 into areas like metabolic disease, with an ultra-long-acting GLP-1 Receptor Agonist program in preclinical development.
2026-02-12 12:58:09
PolyPid aims to complete a rolling NDA submission for its novel antibiotic, D-PLEX100, by the end of Q1 2026, targeting the treatment of abdominal infections. While awaiting FDA feedback on their Phase 3 data, the company is actively engaged in advanced discussions for a strategic US partnership to support the drug's commercialization. Positive trial results are bolstering these partnership talks, underscoring the potential of D-PLEX100.
